Annual report

Period2024-01-01 → 2024-12-31
Filed2025-03-28
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 146
MetricValuePeriodScopeSource row
Revenue¥6.3bn2024-01-01 → 2024-12-31Cons.Net sales
Revenue¥6.1bn2023-01-01 → 2023-12-31Cons.Net sales
Revenue¥5.0bn2022-01-01 → 2022-12-31dCons.Net sales (5-year summary)
Revenue¥11.3bn2021-01-01 → 2021-12-31dCons.Net sales (5-year summary)
Revenue¥17.6bn2020-01-01 → 2020-12-31dCons.Net sales (5-year summary)
Operating income¥629m2024-01-01 → 2024-12-31Cons.Operating income
Operating income−¥1.0bn2023-01-01 → 2023-12-31Cons.Operating income
Ordinary income¥688m2024-01-01 → 2024-12-31Cons.Ordinary income
Ordinary income−¥1.2bn2023-01-01 → 2023-12-31Cons.Ordinary income
Ordinary income−¥3.4bn2022-01-01 → 2022-12-31dCons.Ordinary income loss (5-year summary)
Ordinary income−¥6.1bn2021-01-01 → 2021-12-31dCons.Ordinary income loss (5-year summary)
Ordinary income¥5.5bn2020-01-01 → 2020-12-31dCons.Ordinary income loss (5-year summary)
Profit before tax¥565m2024-01-01 → 2024-12-31Cons.Income before income taxes
Profit before tax−¥3.6bn2023-01-01 → 2023-12-31Cons.Income before income taxes
Net income (owners)¥898m2024-01-01 → 2024-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)−¥3.6bn2023-01-01 → 2023-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)−¥4.9bn2022-01-01 → 2022-12-31dCons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥9.6bn2021-01-01 → 2021-12-31dCons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥3.9bn2020-01-01 → 2020-12-31dCons.Profit loss attributable to owners of parent (5-year summary)
Net income¥898m2024-01-01 → 2024-12-31Cons.Profit loss
Net income−¥3.6bn2023-01-01 → 2023-12-31Cons.Profit loss
Total assets¥12.9bnat 2024-12-31Cons.Assets
Total assets¥13.2bnat 2023-12-31Cons.Assets
Total assets¥15.0bnat 2022-12-31dCons.Total assets (5-year summary)
Total assets¥22.5bnat 2021-12-31dCons.Total assets (5-year summary)
Total assets¥31.8bnat 2020-12-31dCons.Total assets (5-year summary)
Total liabilities¥4.9bnat 2024-12-31Cons.Liabilities
Total liabilities¥6.5bnat 2023-12-31Cons.Liabilities
Net assets / equity¥8.0bnat 2024-12-31Cons.Net assets
Net assets / equity¥6.7bnat 2023-12-31Cons.Net assets
Net assets / equity¥8.0bnat 2022-12-31dCons.Net assets
Net assets / equity¥12.8bnat 2021-12-31dCons.Net assets (5-year summary)
Net assets / equity¥22.8bnat 2020-12-31dCons.Net assets (5-year summary)
Cash and deposits¥4.5bnat 2024-12-31Cons.Cash and deposits
Cash and deposits¥5.5bnat 2023-12-31Cons.Cash and deposits
Cash & equivalents¥4.5bnat 2024-12-31Cons.Cash and cash equivalents
Cash & equivalents¥5.2bnat 2023-12-31Cons.Cash and cash equivalents
Cash & equivalents¥2.8bnat 2022-12-31dCons.Cash and cash equivalents
Cash & equivalents¥5.5bnat 2021-12-31dCons.Cash and cash equivalents (5-year summary)
Cash & equivalents¥4.7bnat 2020-12-31dCons.Cash and cash equivalents (5-year summary)
Operating cash flow¥362m2024-01-01 → 2024-12-31Cons.Net cash provided by used in operating activities
Operating cash flow−¥307m2023-01-01 → 2023-12-31Cons.Net cash provided by used in operating activities
Operating cash flow−¥2.0bn2022-01-01 → 2022-12-31dCons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.6bn2021-01-01 → 2021-12-31dCons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.5bn2020-01-01 → 2020-12-31dCons.Net cash provided by used in operating activities (5-year summary)
Investing cash flow−¥5m2024-01-01 → 2024-12-31Cons.Net cash provided by used in investment activities
Investing cash flow¥1.2bn2023-01-01 → 2023-12-31Cons.Net cash provided by used in investment activities
Investing cash flow¥190m2022-01-01 → 2022-12-31dCons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1.6bn2021-01-01 → 2021-12-31dCons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥2.8bn2020-01-01 → 2020-12-31dCons.Net cash provided by used in investing activities (5-year summary)
Financing cash flow−¥1.2bn2024-01-01 → 2024-12-31Cons.Net cash provided by used in financing activities
Financing cash flow¥1.5bn2023-01-01 → 2023-12-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥997m2022-01-01 → 2022-12-31dCons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥4.0bn2021-01-01 → 2021-12-31dCons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥649m2020-01-01 → 2020-12-31dCons.Net cash provided by used in financing activities (5-year summary)
EPS (basic)¥17.92024-01-01 → 2024-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-76.252023-01-01 → 2023-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-112.262022-01-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-220.522021-01-01 → 2021-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥89.182020-01-01 → 2020-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥88.822020-01-01 → 2020-12-31dCons.Diluted earnings per share (5-year summary)
Net assets per share¥158.67at 2024-12-31Cons.Net assets per share (5-year summary)
Net assets per share¥134.93at 2023-12-31Cons.Net assets per share (5-year summary)
Net assets per share¥184.6at 2022-12-31dCons.Net assets per share (5-year summary)
Net assets per share¥293.88at 2021-12-31dCons.Net assets per share (5-year summary)
Net assets per share¥525.83at 2020-12-31dCons.Net assets per share (5-year summary)
Equity ratio61.7%at 2024-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio51.0%at 2023-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio53.5%at 2022-12-31dCons.Equity to asset ratio (5-year summary)
Equity ratio56.8%at 2021-12-31dCons.Equity to asset ratio (5-year summary)
Equity ratio71.7%at 2020-12-31dCons.Equity to asset ratio (5-year summary)
ROE12.2%2024-01-01 → 2024-12-31Cons.Rate of return on equity (5-year summary)
ROE-48.9%2023-01-01 → 2023-12-31Cons.Rate of return on equity (5-year summary)
ROE-47.0%2022-01-01 → 2022-12-31dCons.Rate of return on equity (5-year summary)
ROE-53.9%2021-01-01 → 2021-12-31dCons.Rate of return on equity (5-year summary)
ROE18.3%2020-01-01 → 2020-12-31dCons.Rate of return on equity (5-year summary)
Employees214at 2024-12-31Cons.Number of employees
Employees208at 2023-12-31Cons.Number of employees
Employees210at 2022-12-31dCons.Number of employees
Employees264at 2021-12-31dCons.Number of employees
Employees274at 2020-12-31dCons.Number of employees
Revenue¥5.5bn2024-01-01 → 2024-12-31StandaloneNet sales
Revenue¥5.4bn2023-01-01 → 2023-12-31StandaloneNet sales
Revenue¥4.6bn2022-01-01 → 2022-12-31dStandaloneNet sales (5-year summary)
Revenue¥10.6bn2021-01-01 → 2021-12-31dStandaloneNet sales (5-year summary)
Revenue¥17.1bn2020-01-01 → 2020-12-31dStandaloneNet sales (5-year summary)
Operating income¥501m2024-01-01 → 2024-12-31StandaloneOperating income
Operating income−¥1.0bn2023-01-01 → 2023-12-31StandaloneOperating income
Ordinary income¥947m2024-01-01 → 2024-12-31StandaloneOrdinary income
Ordinary income−¥1.3bn2023-01-01 → 2023-12-31StandaloneOrdinary income
Ordinary income−¥3.3bn2022-01-01 → 2022-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥5.9bn2021-01-01 → 2021-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥5.5bn2020-01-01 → 2020-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax¥829m2024-01-01 → 2024-12-31StandaloneIncome before income taxes
Profit before tax−¥3.7bn2023-01-01 → 2023-12-31StandaloneIncome before income taxes
Net income¥1.2bn2024-01-01 → 2024-12-31StandaloneProfit loss
Net income−¥3.7bn2023-01-01 → 2023-12-31StandaloneProfit loss
Net income−¥5.0bn2022-01-01 → 2022-12-31dStandaloneNet income loss (5-year summary)
Net income−¥9.3bn2021-01-01 → 2021-12-31dStandaloneNet income loss (5-year summary)
Net income¥3.9bn2020-01-01 → 2020-12-31dStandaloneNet income loss (5-year summary)
Total assets¥12.1bnat 2024-12-31StandaloneAssets
Total assets¥12.2bnat 2023-12-31StandaloneAssets
Total assets¥14.3bnat 2022-12-31dStandaloneTotal assets (5-year summary)
Total assets¥21.9bnat 2021-12-31dStandaloneTotal assets (5-year summary)
Total assets¥31.0bnat 2020-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥4.7bnat 2024-12-31StandaloneLiabilities
Total liabilities¥6.2bnat 2023-12-31StandaloneLiabilities
Net assets / equity¥7.4bnat 2024-12-31StandaloneNet assets
Net assets / equity¥6.0bnat 2023-12-31StandaloneNet assets
Net assets / equity¥7.5bnat 2022-12-31dStandaloneNet assets
Net assets / equity¥12.4bnat 2021-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥22.2bnat 2020-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥3.5bnat 2024-12-31StandaloneCash and deposits
Cash and deposits¥4.1bnat 2023-12-31StandaloneCash and deposits
EPS (basic)¥23.342024-01-01 → 2024-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-78.632023-01-01 → 2023-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-113.642022-01-01 → 2022-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-213.032021-01-01 → 2021-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥89.572020-01-01 → 2020-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (diluted)¥89.212020-01-01 → 2020-12-31dStandaloneDiluted earnings per share (5-year summary)
Dividend per share¥252020-01-01 → 2020-12-31dStandaloneDividend paid per share (5-year summary)
Net assets per share¥147.67at 2024-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥120.52at 2023-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥171.91at 2022-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥284.83at 2021-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥512.14at 2020-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio61.1%at 2024-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio49.1%at 2023-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio52.4%at 2022-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio56.6%at 2021-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio71.6%at 2020-12-31dStandaloneEquity to asset ratio (5-year summary)
ROE17.4%2024-01-01 → 2024-12-31StandaloneRate of return on equity (5-year summary)
ROE-55.1%2023-01-01 → 2023-12-31StandaloneRate of return on equity (5-year summary)
ROE-49.8%2022-01-01 → 2022-12-31dStandaloneRate of return on equity (5-year summary)
ROE-53.6%2021-01-01 → 2021-12-31dStandaloneRate of return on equity (5-year summary)
ROE18.9%2020-01-01 → 2020-12-31dStandaloneRate of return on equity (5-year summary)
Shares issued50,636,900at 2024-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued50,436,900at 2023-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued44,136,900at 2022-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued44,136,900at 2021-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued44,001,900at 2020-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees186at 2024-12-31StandaloneNumber of employees
Employees178at 2023-12-31StandaloneNumber of employees
Employees175at 2022-12-31dStandaloneNumber of employees
Employees226at 2021-12-31dStandaloneNumber of employees
Employees237at 2020-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 58
SegmentItemPeriodValue
Otherother segmentsrevenue2024-01-01 → 2024-12-31¥5m
Otherother segmentsrevenue external2024-01-01 → 2024-12-31¥5m
Otherother segmentssegment assetsat 2024-12-31¥13m
Otherother segmentssegment profit2024-01-01 → 2024-12-31−¥12m
Reconciling Itemsreconcilingcapex2024-01-01 → 2024-12-31¥67m
Reconciling Itemsreconcilingdepreciation2024-01-01 → 2024-12-31¥24m
Reconciling Itemsreconcilingsegment assetsat 2024-12-31¥5.8bn
Reconciling Itemsreconcilingsegment profit2024-01-01 → 2024-12-31−¥837m
Infection Control Businessreportable segmentcapex2024-01-01 → 2024-12-31¥4m
Infection Control Businessreportable segmentdepreciation2024-01-01 → 2024-12-31¥12m
Infection Control Businessreportable segmentemployeesat 2024-12-3144 pure
Infection Control Businessreportable segmentrevenue2024-01-01 → 2024-12-31¥508m
Infection Control Businessreportable segmentrevenue external2024-01-01 → 2024-12-31¥508m
Infection Control Businessreportable segmentsegment assetsat 2024-12-31¥710m
Infection Control Businessreportable segmentsegment profit2024-01-01 → 2024-12-31−¥467m
Pharmaceuticals Businessreportable segmentcapex2024-01-01 → 2024-12-31¥137m
Pharmaceuticals Businessreportable segmentdepreciation2024-01-01 → 2024-12-31¥220m
Pharmaceuticals Businessreportable segmentemployeesat 2024-12-31143 pure
Pharmaceuticals Businessreportable segmentrevenue2024-01-01 → 2024-12-31¥5.8bn
Pharmaceuticals Businessreportable segmentrevenue external2024-01-01 → 2024-12-31¥5.8bn
Pharmaceuticals Businessreportable segmentsegment assetsat 2024-12-31¥6.3bn
Pharmaceuticals Businessreportable segmentsegment profit2024-01-01 → 2024-12-31¥1.9bn
—segment totalemployeesat 2024-12-31187 pure
Total Of Reportable Segments And Otherssegment totalcapex2024-01-01 → 2024-12-31¥142m
Total Of Reportable Segments And Otherssegment totaldepreciation2024-01-01 → 2024-12-31¥232m
Total Of Reportable Segments And Otherssegment totalrevenue2024-01-01 → 2024-12-31¥6.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2024-01-01 → 2024-12-31¥6.3bn
Total Of Reportable Segments And Otherssegment totalsegment assetsat 2024-12-31¥7.1bn
Total Of Reportable Segments And Otherssegment totalsegment profit2024-01-01 → 2024-12-31¥1.5bn
Otherother segmentsrevenue2023-01-01 → 2023-12-31¥5m
Otherother segmentsrevenue external2023-01-01 → 2023-12-31¥5m
Otherother segmentssegment assetsat 2023-12-31¥12m
Otherother segmentssegment profit2023-01-01 → 2023-12-31−¥28m
Reconciling Itemsreconcilingcapex2023-01-01 → 2023-12-31¥68m
Reconciling Itemsreconcilingdepreciation2023-01-01 → 2023-12-31¥135m
Reconciling Itemsreconcilingsegment assetsat 2023-12-31¥6.5bn
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-12-31−¥996m
Infection Control Businessreportable segmentcapex2023-01-01 → 2023-12-31¥89m
Infection Control Businessreportable segmentdepreciation2023-01-01 → 2023-12-31¥44m
Infection Control Businessreportable segmentrevenue2023-01-01 → 2023-12-31¥929m
Infection Control Businessreportable segmentrevenue external2023-01-01 → 2023-12-31¥929m
Infection Control Businessreportable segmentsegment assetsat 2023-12-31¥823m
Infection Control Businessreportable segmentsegment profit2023-01-01 → 2023-12-31−¥1.2bn
Pharmaceuticals Businessreportable segmentcapex2023-01-01 → 2023-12-31¥101m
Pharmaceuticals Businessreportable segmentdepreciation2023-01-01 → 2023-12-31¥525m
Pharmaceuticals Businessreportable segmentrevenue2023-01-01 → 2023-12-31¥5.2bn
Pharmaceuticals Businessreportable segmentrevenue external2023-01-01 → 2023-12-31¥5.2bn
Pharmaceuticals Businessreportable segmentsegment assetsat 2023-12-31¥5.8bn
Pharmaceuticals Businessreportable segmentsegment profit2023-01-01 → 2023-12-31¥1.2bn
Total Of Reportable Segments And Otherssegment totalcapex2023-01-01 → 2023-12-31¥190m
Total Of Reportable Segments And Otherssegment totaldepreciation2023-01-01 → 2023-12-31¥569m
Total Of Reportable Segments And Otherssegment totalrevenue2023-01-01 → 2023-12-31¥6.1bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-01-01 → 2023-12-31¥6.1bn
Total Of Reportable Segments And Otherssegment totalsegment assetsat 2023-12-31¥6.7bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-01-01 → 2023-12-31−¥8m
Infection Control Businessreportable segmentemployeesat 2024-12-3137 pure
Pharmaceuticals Businessreportable segmentemployeesat 2024-12-31122 pure
—segment totalemployeesat 2024-12-31159 pure

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,550
ItemContextValueUnit
Accounts receivable tradePrior1YearInstant1953000000JPY
Accounts receivable tradeCurrentYearInstant2427000000JPY
Write downs of inventoriesPrior1YearDuration404000000JPY
Write downs of inventoriesCurrentYearDuration6000000JPY
Salaries and allowances sgaPrior1YearDuration781000000JPY
Salaries and allowances sgaCurrentYearDuration753000000JPY
Provision for bonuses sgaPrior1YearDuration46000000JPY
Provision for bonuses sgaCurrentYearDuration107000000JPY
Retirement benefit expenses sgaPrior1YearDuration46000000JPY
Retirement benefit expenses sgaCurrentYearDuration72000000JPY
Advertising expenses sgaPrior1YearDuration720000000JPY
Advertising expenses sgaCurrentYearDuration624000000JPY
Promotion expenses sgaPrior1YearDuration259000000JPY
Promotion expenses sgaCurrentYearDuration143000000JPY
Transportation and warehousing expenses sgaPrior1YearDuration192000000JPY
Transportation and warehousing expenses sgaCurrentYearDuration133000000JPY
Commission fee sgaPrior1YearDuration365000000JPY
Commission fee sgaCurrentYearDuration301000000JPY
Research and development expenses sgaPrior1YearDuration245000000JPY
Research and development expenses sgaCurrentYearDuration183000000JPY
Revenues from external customersPrior1YearDuration_jpcrp030000-asr_E22560-000PharmaceuticalsBusinessReportableSegmentsMember5185000000JPY
Revenues from external customersPrior1YearDuration_jpcrp030000-asr_E22560-000InfectionControlBusinessReportableSegmentsMember929000000JPY
Revenues from external customersPrior1YearDuration_OtherReportableSegmentsMember5000000JPY
Revenues from external customersPrior1YearDuration_TotalOfReportableSegmentsAndOthersMember6120000000JPY
Revenues from external customersPrior1YearDuration_ReconcilingItemsMember-JPY
Revenues from external customersPrior1YearDuration6120000000JPY
Transactions with other segmentsPrior1YearDuration_jpcrp030000-asr_E22560-000PharmaceuticalsBusinessReportableSegmentsMember-JPY
Transactions with other segmentsPrior1YearDuration_jpcrp030000-asr_E22560-000InfectionControlBusinessReportableSegmentsMember-JPY
Transactions with other segmentsPrior1YearDuration_OtherReportableSegmentsMember-JPY
Transactions with other segmentsPrior1YearDuration_TotalOfReportableSegmentsAndOthersMember-JPY
Transactions with other segmentsPrior1YearDuration_ReconcilingItemsMember-JPY
Transactions with other segmentsPrior1YearDuration-JPY
Net salesPrior1YearDuration_jpcrp030000-asr_E22560-000PharmaceuticalsBusinessReportableSegmentsMember5185000000JPY
Net salesPrior1YearDuration_jpcrp030000-asr_E22560-000InfectionControlBusinessReportableSegmentsMember929000000JPY
Net salesPrior1YearDuration_OtherReportableSegmentsMember5000000JPY
Net salesPrior1YearDuration_TotalOfReportableSegmentsAndOthersMember6120000000JPY
Net salesPrior1YearDuration_ReconcilingItemsMember-JPY
Net salesPrior1YearDuration6120000000JPY
Operating incomePrior1YearDuration_jpcrp030000-asr_E22560-000PharmaceuticalsBusinessReportableSegmentsMember1212000000JPY
Operating incomePrior1YearDuration_jpcrp030000-asr_E22560-000InfectionControlBusinessReportableSegmentsMember-1192000000JPY
Operating incomePrior1YearDuration_OtherReportableSegmentsMember-28000000JPY
Operating incomePrior1YearDuration_TotalOfReportableSegmentsAndOthersMember-8000000JPY
Operating incomePrior1YearDuration_ReconcilingItemsMember-996000000JPY
Operating incomePrior1YearDuration-1005000000JPY
AssetsPrior1YearInstant_jpcrp030000-asr_E22560-000PharmaceuticalsBusinessReportableSegmentsMember5850000000JPY
AssetsPrior1YearInstant_jpcrp030000-asr_E22560-000InfectionControlBusinessReportableSegmentsMember823000000JPY
AssetsPrior1YearInstant_OtherReportableSegmentsMember12000000JPY
AssetsPrior1YearInstant_TotalOfReportableSegmentsAndOthersMember6686000000JPY
AssetsPrior1YearInstant_ReconcilingItemsMember6534000000JPY
AssetsPrior1YearInstant13220000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 24 of 24 passed
balance sheet identityconsolidated 2023-12-31pass rounding
balance sheet identityconsolidated 2024-12-31pass rounding
balance sheet identitynon_consolidated 2023-12-31pass
balance sheet identitynon_consolidated 2024-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net assetsconsolidated 2023-12-31pass
statement vs summary · net assetsconsolidated 2024-12-31pass
statement vs summary · net assetsnon_consolidated 2022-12-31pass
statement vs summary · net assetsnon_consolidated 2023-12-31pass
statement vs summary · net assetsnon_consolidated 2024-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-12-31pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-12-31pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-12-31pass
statement vs summary · revenueconsolidated 2023-01-01/2023-12-31pass
statement vs summary · revenueconsolidated 2024-01-01/2024-12-31pass
statement vs summary · revenuenon_consolidated 2023-01-01/2023-12-31pass
statement vs summary · revenuenon_consolidated 2024-01-01/2024-12-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass
statement vs summary · total assetsconsolidated 2024-12-31pass
statement vs summary · total assetsnon_consolidated 2023-12-31pass
statement vs summary · total assetsnon_consolidated 2024-12-31pass